Literature DB >> 10656226

Population-based genetic screening for the estimation of Type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci.

S Nejentsev1, M Sjöroos, T Soukka, M Knip, O Simell, T Lövgren, J Ilonen.   

Abstract

AIMS: To improve sensitivity and specificity of the diabetes risk assessment of the population-based genetic screening used in the Finnish Diabetes Prediction and Prevention (DIPP) trial.
METHODS: One thousand consecutive newborns enrolled in the DIPP were compared with 316 samples from children with Type 1 diabetes mellitus. A modification of the previously described technique based on hybridization of relevant PCR products with five lanthanide-labelled probes detected by time-resolved fluorometry (TRF) was used. A new probe was designed and allowed discrimination between DQB1*0602 and 0603 alleles, in addition to DQB1*02, *0301 or *0302, each of which required specific probes. A new, added screening strategy was developed for individuals carrying low-risk genotypes through specific typing of DQA1 *05 and *0201 alleles in DQB1*02 positive, and DRB1 typing for DR4 subtypes in DQB1*0302 positive subjects, with a new specifically designed high-resolution TRF-based DR4 subtyping technique.
RESULTS: This two-step screening approach enhanced the sensitivity of the detection of genetic risk for Type 1 diabetes mellitus in this cohort up to 85.4%. In the general population cohort, 24.4% were identified for prospective follow-up, 2.6% of these are expected to develop Type 1 diabetes mellitus before the age of 15 years. Exclusive typing for HLA-DQB1 locus as an alternative screening strategy had sensitivities of 26.3-77.2% with general population cohorts of 2.3-23.1% identified for follow-up.
CONCLUSIONS: The described strategy for genetic prediction of Type 1 diabetes mellitus relies on the convenient genotyping procedure and could be applied in large scale screening projects such as DIPP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10656226     DOI: 10.1046/j.1464-5491.1999.00186.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  40 in total

1.  Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes--indication of an increased environmental pressure?

Authors:  R Hermann; M Knip; R Veijola; O Simell; A-P Laine; H K Akerblom; P-H Groop; C Forsblom; K Pettersson-Fernholm; J Ilonen
Journal:  Diabetologia       Date:  2003-03-18       Impact factor: 10.122

2.  HLA-DR-DQ haplotypes and genotypes in Finnish patients with rheumatoid arthritis.

Authors:  S Laivoranta-Nyman; T Möttönen; R Hermann; J Tuokko; R Luukkainen; M Hakala; P Hannonen; M Korpela; U Yli-Kerttula; A Toivanen; J Ilonen
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

3.  The association between HLA DQ genetic polymorphism and type 1 diabetes in a case-parent study conducted in an admixed population.

Authors:  Adriana Mimbacas; Fernando Pérez-Bravo; Jose Luis Santos; Carmen Pisciottano; Rosario Grignola; Gerardo Javiel; Ana Maria Jorge; Horacio Cardoso
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

4.  The association of CTLA-4 and HLA class II autoimmune risk genotype with regulatory T cell marker expression in 5-year-old children.

Authors:  C-O Jonson; M Hedman; M Karlsson Faresjö; R Casas; J Ilonen; J Ludvigsson; O Vaarala
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

5.  Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk.

Authors:  V Parikka; K Näntö-Salonen; M Saarinen; T Simell; J Ilonen; H Hyöty; R Veijola; M Knip; O Simell
Journal:  Diabetologia       Date:  2012-03-23       Impact factor: 10.122

Review 6.  Environmental factors in the etiology of type 1 diabetes, celiac disease, and narcolepsy.

Authors:  Åke Lernmark
Journal:  Pediatr Diabetes       Date:  2016-07       Impact factor: 4.866

7.  Natural Development of Antibodies against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Protein Antigens during the First 13 Years of Life.

Authors:  Igor C Borges; Dafne C Andrade; Maria Regina A Cardoso; Jorma Toppari; Mari Vähä-Mäkilä; Jorma Ilonen; Mikael Knip; Heikki Hyöty; Riitta Veijola; Olli Simell; Tuomas Jartti; Helena Käyhty; Olli Ruuskanen; Cristiana M Nascimento-Carvalho
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

8.  A simulation model for estimating direct costs of type 1 diabetes prevention.

Authors:  Jarmo Hahl; Tuula Simell; Antti Kupila; Päivi Keskinen; Mikael Knip; Jorma Ilonen; Olli Simell
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome.

Authors:  H Viskari; J Paronen; P Keskinen; S Simell; B Zawilinska; I Zgorniak-Nowosielska; S Korhonen; J Ilonen; O Simell; A-M Haapala; M Knip; H Hyöty
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

10.  Age at development of type 1 diabetes- and celiac disease-associated antibodies and clinical disease in genetically susceptible children observed from birth.

Authors:  Satu Simell; Sanna Hoppu; Tuu Simell; Marja-Riitta Ståhlberg; Markku Viander; Taina Routi; Ville Simell; Riitta Veijola; Jorma Ilonen; Heikki Hyöty; Mikael Knip; Olli Simell
Journal:  Diabetes Care       Date:  2010-01-07       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.